November 17, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Vascular Solutions, Inc. (NASDAQ:VASC) shares over potential securities laws violations by Vascular Solutions and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Vascular Solutions, Inc. (NASDAQ:VASC) concerning whether a series of statements by Vascular Solutions regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Vascular Solutions, Inc. reported that its annual Total Revenue rose from $89.96 million in 2011 to $110.50 million in 2013 and that its respective Net Income increased from $9.74 million to $11.14 million.

Shares of Vascular Solutions, Inc. (NASDAQ:VASC) grew from $9.97 per share in November 2011 to as high as $30.96 per share on November 13, 2014.

Then on November 13, 2014, a federal grand jury indicted Vascular Solutions CEO, Howard Root, on charges he conspired to sell a varicose-vein treatment device for unapproved uses. The nine count indictment alleges Vascular Solutions, Inc improperly marketed its Vri-Lase device kit for use on veins deep in the leg, even though it was only approved for use on superficial blood vessels and a clinical trial showed adverse events when Vari-Lase was used on deeper veins.

Shares of Vascular Solutions, Inc dropped from almost $31 per share on November 13, 2014, to as low as $23.23 per share on November 13, 2014.